A Phase II, Open-label, Single-arm, Multicenter Study to Evaluate Efficacy and Safety of Pembrolizumab Monotherapy in Subjects With Advanced Recurrent Ovarian Cancer (KEYNOTE-100)
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 14 Aug 2017
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Ovarian cancer
- Focus Therapeutic Use
- Acronyms KEYNOTE-100
- Sponsors Merck Sharp & Dohme
- 10 Jun 2017 Biomarkers information updated
- 24 May 2017 Planned End Date changed from 7 Oct 2019 to 18 Sep 2019.
- 24 May 2017 Planned primary completion date changed from 7 Oct 2019 to 18 Sep 2019.